26 years of historical data (2000–2025) · Healthcare · Medical - Pharmaceuticals
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
PetMed Express, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $48M | $86M | $98M | $330M | $525M | $708M | $577M | $467M | $853M | $410M | $363M |
| Enterprise Value | $-5387200 | $33M | $44M | $227M | $414M | $589M | $473M | $366M | $775M | $352M | $325M |
| P/E Ratio → | -7.67 | — | — | 64.96 | 24.81 | 23.14 | 22.31 | 12.38 | 22.94 | 17.21 | 17.56 |
| P/S Ratio | 0.21 | 0.38 | 0.36 | 1.29 | 1.92 | 2.33 | 2.03 | 1.65 | 3.12 | 1.65 | 1.55 |
| P/B Ratio | 0.56 | 1.01 | 1.01 | 3.00 | 3.69 | 5.01 | 4.44 | 3.47 | 7.37 | 4.40 | 4.36 |
| P/FCF | — | — | — | 14.65 | 31.36 | 18.80 | 15.80 | 10.49 | 23.26 | 11.21 | 393.01 |
| P/OCF | 10.25 | 18.29 | 22.63 | 11.88 | 28.39 | 17.66 | 14.86 | 10.34 | 22.82 | 8.69 | 17.23 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.14 | 0.16 | 0.89 | 1.51 | 1.94 | 1.67 | 1.29 | 2.83 | 1.41 | 1.39 |
| EV / EBITDA | -0.98 | 5.91 | 466.54 | 22.50 | 14.56 | 17.87 | 14.25 | 7.57 | 14.29 | 9.05 | 9.80 |
| EV / EBIT | — | — | — | 30.52 | 15.30 | 19.29 | 13.97 | 7.46 | 14.41 | 9.27 | 10.04 |
| EV / FCF | — | — | — | 10.08 | 24.73 | 15.65 | 12.96 | 8.23 | 21.13 | 9.61 | 352.23 |
Margins and return-on-capital ratios measuring operating efficiency
PetMed Express, Inc. earns an operating margin of -0.7%. Operating margins have compressed from 2.6% to -0.7% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -6.9% indicates the company is currently destroying shareholder equity.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 30.5% | 30.5% | 28.4% | 27.7% | 27.6% | 27.8% | 28.6% | 33.6% | 35.7% | 31.8% | 32.5% |
| Operating Margin | -0.7% | -0.7% | -2.5% | 2.6% | 9.4% | 10.1% | 10.9% | 16.3% | 19.0% | 15.0% | 13.8% |
| Net Profit Margin | -2.8% | -2.8% | -2.7% | 2.0% | 7.7% | 7.9% | 9.1% | 13.3% | 13.6% | 9.6% | 8.8% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -6.9% | -6.9% | -7.2% | 4.1% | 14.9% | 17.6% | 19.5% | 30.1% | 35.7% | 27.0% | 25.9% |
| ROA | -3.9% | -3.9% | -4.4% | 3.0% | 11.6% | 14.0% | 16.7% | 26.1% | 30.1% | 23.5% | 23.8% |
| ROIC | -3.1% | -3.1% | -21.0% | 25.9% | 71.9% | 93.8% | 76.9% | 96.3% | 108.0% | 70.1% | 56.9% |
| ROCE | -1.7% | -1.7% | -6.6% | 5.1% | 18.0% | 22.3% | 23.2% | 36.6% | 49.4% | 42.2% | 40.8% |
Solvency and debt-coverage ratios — lower is generally safer
PetMed Express, Inc. carries a Debt/EBITDA ratio of 0.2x, which is very conservative (95% below the sector average of 3.3x). The company holds a net cash position — cash of $55M exceeds total debt of $996000, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | 0.02 | 0.01 | — | — | — | — | — | — | — |
| Debt / EBITDA | 0.18 | 0.18 | 15.47 | 0.10 | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.63 | -0.56 | -0.94 | -0.78 | -0.84 | -0.80 | -0.75 | -0.67 | -0.63 | -0.45 |
| Net Debt / EBITDA | -9.75 | -9.75 | -572.79 | -10.21 | -3.90 | -3.60 | -3.12 | -2.08 | -1.44 | -1.51 | -1.14 |
| Debt / FCF | — | — | — | -4.57 | -6.63 | -3.15 | -2.84 | -2.26 | -2.12 | -1.60 | -40.78 |
| Interest Coverage | — | — | — | — | — | 25.23 | — | — | — | — | — |
Net cash position: cash ($55M) exceeds total debt ($996000)
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.26x means PetMed Express, Inc. can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has declined from 2.27x to 1.26x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.26 | 1.26 | 1.30 | 2.27 | 4.55 | 3.59 | 5.30 | 6.79 | 5.81 | 4.46 | 9.55 |
| Quick Ratio | 1.00 | 1.00 | 0.90 | 1.94 | 3.57 | 2.82 | 4.57 | 5.64 | 4.52 | 3.35 | 5.93 |
| Cash Ratio | 0.87 | 0.87 | 0.77 | 1.81 | 3.35 | 2.64 | 4.26 | 5.40 | 4.30 | 3.20 | 5.31 |
| Asset Turnover | — | 1.53 | 1.61 | 1.51 | 1.55 | 1.62 | 1.83 | 1.84 | 2.03 | 2.21 | 2.60 |
| Inventory Turnover | 9.74 | 9.74 | 6.88 | 9.77 | 6.10 | 6.37 | 11.34 | 8.80 | 7.54 | 8.40 | 6.19 |
| Days Sales Outstanding | — | 3.73 | 4.37 | 2.48 | 2.55 | 3.11 | 4.94 | 3.27 | 3.06 | 2.65 | 2.68 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
PetMed Express, Inc. returns 0.4% to shareholders annually primarily through dividends.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 0.4% | 0.2% | 12.7% | 7.4% | 4.6% | 3.2% | 3.8% | 4.7% | 2.0% | 3.8% | 4.0% |
| Payout Ratio | — | — | — | 477.4% | 115.6% | 94.8% | 84.3% | 58.1% | 46.9% | 65.1% | 71.4% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | 1.5% | 4.0% | 4.3% | 4.5% | 8.1% | 4.4% | 5.8% | 5.7% |
| FCF Yield | — | — | — | 6.8% | 3.2% | 5.3% | 6.3% | 9.5% | 4.3% | 8.9% | 0.3% |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 2.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.4% | 0.2% | 12.7% | 7.4% | 4.6% | 3.2% | 5.8% | 4.7% | 2.0% | 3.8% | 4.0% |
| Shares Outstanding | — | $21M | $20M | $20M | $20M | $20M | $20M | $20M | $20M | $20M | $20M |
Compare PETS with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| $48M | -7.7 | -1.0 | — | 30.5% | -0.7% | -6.9% | -3.1% | 0.2 | |
| $10B | 26.0 | 42.8 | 21.7 | 29.2% | 0.9% | 101.8% | 28.0% | 2.2 | |
| $752M | 86.8 | 5.9 | 2.4 | 38.7% | 2.0% | 0.8% | 2.9% | 4.3 | |
| $3B | 21.2 | 16.6 | 221.4 | 38.6% | 8.6% | 12.3% | 5.3% | 3.1 | |
| $7B | 50.3 | 42.7 | 89.6 | 59.3% | 5.2% | 25.2% | 10.7% | 6.4 | |
| $1B | -6.1 | 15.1 | 4.4 | 69.5% | -10.4% | -13.9% | -11.5% | 10.4 | |
| $13M | -1.5 | 5.1 | — | 83.7% | -0.9% | -0.6% | -0.6% | 5.3 | |
| $1B | -2.3 | — | — | -62.0% | -867.9% | -59.5% | -95.8% | — | |
| $37B | 14.5 | 10.8 | 16.1 | 70.5% | 38.0% | 66.0% | 26.9% | 2.3 | |
| $12B | -51.1 | 16.6 | 42.2 | 43.5% | 5.3% | -3.7% | 1.9% | 4.3 | |
| $2B | 36.3 | 15.7 | 41.8 | 30.9% | 8.5% | 17.8% | 9.8% | 4.9 | |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Includes 30+ ratios · 26 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorDCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationSide-by-side business, growth, and profitability comparison vs Chewy, Inc..
Start ComparisonQuick answers to the most common questions about buying PETS stock.
PetMed Express, Inc.'s current P/E ratio is -7.7x. The historical average is 22.4x.
PetMed Express, Inc.'s current EV/EBITDA is -1.0x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 12.7x.
PetMed Express, Inc.'s return on equity (ROE) is -6.9%. The historical average is 13.8%.
Based on historical data, PetMed Express, Inc. is trading at a P/E of -7.7x. Compare with industry peers and growth rates for a complete picture.
PetMed Express, Inc.'s current dividend yield is 0.38%.
PetMed Express, Inc. has 30.5% gross margin and -0.7% operating margin.
PetMed Express, Inc.'s Debt/EBITDA ratio is 0.2x, indicating low leverage. A ratio below 2x is generally considered financially healthy.